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Many tissues contain adult mesenchymal stem cells (MSCs), which may be used in tissue regeneration therapies. However, the
MSC availability in most tissues is limited which demands expansion in vitro following isolation. Like many developing cells, the
state of MSCs is affected by the surrounding microenvironment, and mimicking this natural microenvironment that supports
multipotent or differentiated state in vivo is essential to understand for the successful use of MSC in regenerative therapies. Many
researchers are, therefore, optimizing cell culture conditions in vitro by altering growth factors, extracellular matrices, chemicals,
oxygen tension, and surrounding pH to enhance stem cells self-renewal or differentiation. Insulin-like growth factors (IGFs) system
has been demonstrated to play an important role in stem cell biology to either promote proliferation and self-renewal or enhance
differentiation onset and outcome, depending on the cell culture conditions. In this review, we will describe the importance of IGFs,
IGF-1 and IGF-2, in development and in the MSC niche and how they affect the pluripotency or differentiation towards multiple
lineages of the three germ layers.

1. Introduction
Currently, many diseases associated with organ failure and
degeneration which are untreatable by pharmaceuticals or
organ replacement have seen the promise in cell-replacement
and tissue regeneration therapies [1]. Such diseases include
endocrine (diabetes), neurodegenerative diseases (Parkinson’s, Alzheimer’s, and Huntington’s), and cardiovascular
diseases (myocardial infarction and peripheral vascular
ischemia) and injuries or chronic conditions in the cornea,
skeletal muscle, skin, joints, and bones [2]. Stem cells have
the potential for tissue/organ repair, replacement of dying
cells, and promoting the survival of damaged tissues [3]. In
addition, with the ability to generate induced pluripotent
stem cells from the recipient’s own somatic cells [4–6] and the

availability of new gene editing technologies (e.g., CRISPRCas9 and TALEN) [7, 8], the use of stem cells in many genetic
and acquired diseases is closer to reality in the near future.
Adult mesenchymal stem cells (MSCs) are multipotent
cells with a defined capacity for self-renewal and differentiation into cell types of all three germ layers depending on their
origin. Unlike embryonic stem cells, MSCs have less ethical
controversies and lower tumorigenicity; however, they have
restricted differentiation potential [9]. Recent research has
also demonstrated a transdifferentiation ability of MSCs from
cells of one germ layer to another [10]. In addition, MSCs have
an immunomodulatory effect to reduce an immune response
and are able to be engrafted successfully in therapy resistant
graft-versus-host disease [3]. The existence of multipotent
stem cells in adult tissues was first described by Till and

2
McCulloch in 1961 [11] and was followed by the isolation
of MSCs from bone marrow by Friedenstein in 1968 [12].
Since then, MSCs have been isolated from most mature
organs and tissues including skeletal muscle [13], adipose
tissue [14], deciduous teeth [15], umbilical cord blood and
placenta [16], peripheral blood [17], and brain [18]. Several
biological markers characterize MSCs of different origins to
be positive for CD73, CD105, CD29, CD44, CD71, CD90,
CD106, CD120a, and CD124 and negative for CD117, CD34,
CD45, and CD14 [19–21]. MSCs have been demonstrated to
differentiate predominantly into mesodermal cells including
osteogenic, chondrogenic, adipogenic [22], and endothelial
[23] lineages. Also, MSCs can differentiate towards ectodermal lineages including corneal [24, 25] and neuronal cells [26]
and also can differentiate towards insulin-producing cells of
the endodermal endocrine pancreatic lineage [27].
Stem cell “niche” is a paracellular microenvironment
that includes cellular and noncellular components from
local and systemic sources that regulate stem cell pluripotency or multipotency, proliferation, differentiation, survival,
and localization [28]. Stem cells are maintained by the
surrounding microenvironment via several cues including
physical, structural, neural, humoral, paracrine, autocrine,
and metabolic interactions [29]. Therefore, a combination
of different microenvironmental signals that are generated
during development, healing, or disease states is capable of
regulating the tissue regeneration process leading to proliferation, differentiation, or quiescence [30]. In this review, we
will focus on the role of insulin-like growth factors (IGFs) in
the MSC niche (Figure 1).

2. Insulin-Like Growth Factor System: Ligands,
Receptors, and Binding Proteins
Insulin-like growth factors (IGFs; IGF-1 and IGF-2) are
two small polypeptides (∼7 kDa) that regulate survival, selfrenewal, and differentiation of many types of cells, including
stem cells [31]. In the systemic circulation in postnatal life,
IGF-1 levels are regulated by growth hormone (GH), which
induces IGF expression and is released by the liver and
accounts for 70–90% of circulating IGFs [32]. Knockdown of
Igf-1 from postnatal murine liver accounted for 75% reduction in circulating IGF-1 levels accompanied by a fourfold
increase in GH, which can lead to insulin resistance [33].
Even in the absence of hepatic IGF-1, postnatal growth is
not affected in mice. This is likely due to extrahepatic tissue
expression of IGFs in a paracrine/autocrine fashion, such as
in the bone, brain, lung, uterus, ovaries, adipose tissue, and
muscle [34]. Under this condition, serum IGF concentrations
are regulated by several factors including gender, age, and
nutrition status, leading to a variable range of IGF-1 (264–
789 ng/mL) and IGF-2 (702–1042 ng/mL) in healthy individuals [35]. In prenatal (embryonic/fetal) life, the regulation of
the synthesis of IGF-1 and IGF-2 by many different organs
and tissues is less well understood. Most likely, the synthesis
is regulated by local (paracrine) factors and cues such as
nutrient status, oxygen tension, biochemistry, extracellular
matrix, and other growth factors in addition to endocrine
factors. Importantly, the IGFs are synthesized as required
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by the developmental and physiological cues within the
extracellular and intracellular environment. It is likely that
the fate of mesenchymal stem cells which reside in the
paracellular niches in adult tissues is regulated by the tissue
microenvironment.
At the molecular level, IGF-1 shares more than 60%
sequence homology with IGF-2 and 50% with proinsulin
[42, 43]. IGFs signal mainly via the IGF-1 receptor (IGF-1R),
which has the highest binding affinity (Kd of 1 nM) towards
IGF-1, followed by 10-fold lower affinity to IGF-2 [44]. IGF-1R
is a receptor-tyrosine-kinase (RTK) which shares a structural
homology domain with the insulin receptor (IR). In turn,
IR is expressed in two isoforms, IR-A and IR-B, and can
form hybrid receptors (HR-A and HR-B) with the IGF-1R,
which binds to both IGFs with variable affinities [45]. Unlike
IGF-1, IGF-2 binds to its specific receptor, IGF-2R, and,
similar to insulin, it can bind to IR-A [46]. IGF-1R, IR, and
HRs are mitogenic RTKs, while IGF-2R is not. Therefore,
different receptor and ligand combinations can cause variable
signaling outcomes, especially in stem cells. Few studies
have been reported on the effects of IGF-1 on the growth,
differentiation, and migratory capacity of mesenchymal stem
cells [36, 38, 47]; however, the expression of different IGF
receptors, insulin receptors, and hybrid receptors and their
relative roles in pluripotency and differentiation have not
been well studied.
Circulating IGFs are bound to six soluble (∼30 kDa)
IGF-binding proteins (IGFBPs, 1–6), which determine the
bioavailability of free IGF ligand in the extracellular vicinity
of the receptors, thus modifying the IGF actions [48]. Under
normal physiological conditions, IGFs bind IGFBPs with
greater affinity than they bind IGF-1R [49–51]. IGFBPs
interaction with IGFs occurs via noncovalent binding [52]
that protects them from degradation by increasing their
half-life [53, 54] and facilitates delivery to specific tissues.
Therefore, IGFBPs play an important role in IGF-regulated
cell metabolism, development, and growth [55]. In addition,
it has become apparent that the IGFBPs can be expressed and
maintained within the cellular microenvironment and have
additional functions independent of regulating IGFs [56].
The role of IGFBPs in MSC fate is currently being delineated
and will be mentioned briefly in this review.

3. Insulin-Like Growth Factor System:
Signaling Cascades
IGF-1R is a transmembrane tetramer receptor that exists
as heterodimers composed of two 𝛼 and 𝛽 hemireceptors
linked by disulfide bonds in a 𝛽–𝛼–𝛼–𝛽 structure [57].
Upon ligand binding, the downstream signal of IGF-1R is
dependent on the differential phosphorylation pattern of its
𝛽-subunit and the resultant tyrosine residues available to
initiate mitogenic signals, mainly through the phosphoinositide 3-kinase (PI3K), AKT/PKB, and the extracellular signalregulated kinase (ERK1/2) [55, 58, 59]. In this manner, IGF-1R
can induce transcriptional activity to promote survival, selfrenewal, and differentiation of MSCs [60, 61].
Upon activation of the extracellular 𝛼 subunits of the
IGF-1R, autophosphorylation in the tyrosine residues on
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Figure 1: Stem cell niche in vivo. The stem cell niche is a complex compartment surrounding mesenchymal stem cells (MSCs) directing
their identity preservation via cellular and acellular components. Various clues and signals are exchanged between MSCs, stromal cells, and
progenitor cells and the extracellular matrix containing different soluble factors, oxygen tension, and pH. Therefore, MSC niche manipulates
the stemness state of MSCs following growth and regeneration demand. IGFs can signal via paracrine/autocrine (produced locally by the
tissue) or endocrine (delivered by blood supply) routes to interact with IGF-1 receptor, IGF-2 receptor, or the insulin receptor on MSCs
and other cells. IGFBPs (extracellular and/or intracellular actions) can modify IGF actions and affect their stability and degradation. Other
receptors and integrins are expressed in MSCs and can be affected by extracellular microenvironment. MSC differentiation occurs by signal
transduction which controls the shutdown of pluripotency-associated genes, such as OCT4, SOX2, and NANOG, for the upregulation of
differentiation genes. For example, MSCs can give rise to all mesodermal lineages depending on the transcription factor expressed to generate
adipose, cartilage, bone, and muscle. Also, transdifferentiation of MSCs into endodermal and ectodermal lineages can occur, as reported by
in vitro studies.

𝛽-subunits creates high affinity binding sites for signaling
adaptor molecules and substrates. For the ERK1/2 signaling
pathway, SHC interacts directly with the IGF-1R𝛽 which
recruits GRB2 that interacts with SOS that subsequently
activates c-RAS leading to the sequential phosphorylation
of RAF, MEK1/2, and then ERK1/2 [42, 62–66]. To activate
the PI3K/AKT signaling, p85, the regulatory subunit of
PI3K, interacts directly with IGF-1R𝛽 independent of SHC
binding [67]. IRS-1 is a main target of the IGF-1R, implicated
in the mitogenic effect of IGF-1R, inhibition of apoptosis,
and transformation, whereas its downregulation has been
associated with the inhibition of differentiation and the
induction of apoptosis [58, 68]. The phosphorylation of IRS-1
amplifies the IGF-1R signaling by indirectly recruiting GRB2
to transduce ERK1/2 signaling [62] or p85 to transduce PI3K

signaling [69]. Therefore, surrounding microenvironmental
inputs would define stem cell behavior depending on receptor
activation and the combination of signaling cascades.

4. The Role of IGFs in
Growth and Development
During development, circulating IGF levels correlate proportionally with placental and fetal weights, and reduced levels
due to poor maternal-nutrition have been suggested to lead
to fetal growth restriction [70]. In human pregnancies, IGFs
play an early role in promoting proliferation/differentiation
and preventing cell apoptosis of various types of placental
cells [61]. In mice, knockout of Igf-1 or Igf-1r causes restricted
growth (<60% of wild-type) and a premature death of
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newborn embryos. Most pups with Igf-1r−/− are unable to
survive due to the lack of functional muscles required for
breathing, while some mouse lines with Igf-1−/− will survive
with deficits in major organs [71–73]. On the other hand,
Igf-2 knockout mice (indistinguishable between homozygous
and heterozygous) are viable at 60% birthweight of wildtype [74]. Double mutants for Igf-1 and Igf-2 are severely
growth-deficient (30% of wild-type) and die shortly after
birth of respiratory failure. Although both IGFs have an
additive effect in embryonic development, IGF-1 is more
important in postnatal growth, while IGF-2 is important
for prenatal fetoplacental growth. Hence, IGF-1 and IGF2 stimulate both proliferation and terminal differentiation
of many organs and tissues in developing embryos and
adult life. Due to the initial description of Igf-1, Igf-2,
and Igf-1r null mice using classic knockout methodology,
mice with tissue-specific knockout of these genes have been
generated using Cre/loxP conditional knockout strategies
with interesting and variable phenotypes [75–78]. The major
differences between the models are the tissue/cell-specificity
and the timing of the null mutation (prenatal or postnatal).
Most of the conditional targeted models are generated with
gene targeting after birth to allow examination of the role
of Igf-1 and Igf-1r in postnatal development without the
ability to discriminate null mutation in stem or somatic cells.
In classic knockout models, gene targeting occurs in the
embryonic stem cells, allowing us to examine the impact of
Igf genes in stem cells. However, only very few reports are
available investigating the impact of the knockout of Igf-1
and Igf-1r in stem cells. Knockout of Igf-1r in adult neural
stem cells maintains youthful characteristics of the olfactory
bulb neurogenesis within the aging brain by increasing the
cumulative neuroblast production and enhancing neuronal
integration into the olfactory bulb, suggesting a gain of
function during aging [79].

5. The Role of IGFs in MSC
Multipotency and Self-Renewal
MSCs isolated from different tissues, such as bone marrow,
adipose tissue, placental chorionic villi, and fetal membranes,
express and secrete IGF-1 and/or IGF-2 in vitro [80–83]. It
was shown that ectopic IGF-1 expression in MSCs enhances
their proliferation with lower apoptosis [84]. In this study,
autocrine IGF-1 levels maintain an elevated baseline activity
of ERK1/2 signaling required for enhanced self-renewal
(higher OCT4), endodermal (higher CYP51) and mesodermal (higher SM22𝛼) potential, but weakened neuronal potential (lower Nestin) [84]. Another growth factor which is basic
fibroblast growth factor (bFGF) was shown to be required
in maintaining stemness and proliferation in hESCs [31, 85]
and in MSCs [80, 86, 87]. Further investigation showed that
this bFGF effect was mediated via the IGF system that is
upregulated by an autonomous expression of IGF-1R, IGF-1,
and IGF-2, as shown in umbilical cord MSCs [86]. Although
both IGF-1 and IGF-2 are involved in mediating stem cell
fate changes, IGF-2 appears to be more prominent than IGF1 in promoting MSC pluripotency/self-renewal. In hESCs,
one study showed that IGF-2, secreted by spontaneously
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differentiated autologous fibroblast-like cells in response to
bFGF, is required to maintain hESC pluripotency and selfrenewal via the signaling of IGF-1R [31]. However, one study
showed that hESCs pluripotency/self-renewal maintenance
can be independent of IGF-2 secretion only when MSCs are
used as a feeder layer [88]. A study, in human dental pulp
MSCs (hDSCs), confirmed that IGF-1R is required for MSC
multipotency and can be regarded as a selection marker for
stemness, just similar to OCT4 and SOX2 [89]. In placental
MSCs (PMSCs), IGF-2 is upregulated by low oxygen tension
and is required to maintain MSC multipotency [80, 87]. Also,
in neural stem cells (NSCs), IGF-2 was shown to play an
important role in maintaining self-renewal [90]. In these
NSCs, the IGF-2 self-renewal properties were mediated via
A-isoform of IR (IR-A), independent of IGF-1R or IGF2R [91]. For a more detailed review on insulin and IGF
receptor signaling in neural stem cells, please see Ziegler et
al. (2015) [92]. We verified the role of IR-A in PMSC, where
we showed an elevated expression level of IR-A versus IR-B;
and both IGF-1 and IGF-2 promote increased proliferation
and self-renewal with a requirement that both IGF-1R and
IR must be present [80]. Although IGF-1R and IR can form
hybrid receptors, the role of hybrid receptor in maintaining
stem cell fate (ESCs or MSCs) and pluripotency is yet to be
confirmed.

6. Induction of Same-Origin MSCs
towards Different Lineages
In vitro, MSC differentiation can be initiated via extrinsic stimulation by growth-factor-mediated differentiation
[93] that requires withdrawing maintenance growth factors and adding differentiation promoting growth factors
and chemicals [28, 29]. Differentiation factors can include
butylated hydroxyanisole and NGF for neuronal differentiation; BMP-12 for tenocyte differentiation; dexamethasone,
3-isobutyl-1-methylxanthine, insulin, and indomethacin for
adipogenic differentiation; monothioglycerol, HGF, oncostatin, dexamethasone, FGF4, insulin, transferrin, and selenium for hepatocytic differentiation; b-FGF and VEGF
for endothelial differentiation; TGF-𝛽1, insulin, transferrin,
dexamethasone, and ascorbic acid for chondrogenic differentiation; insulin, transferrin, and selenium for skeletal
myogenic differentiation; and dexamethasone, ascorbic acid,
and 𝛽-glycerophosphate for osteogenic differentiation [94–
99]. Therefore, the same MSC population in the mesoderm
exposed to different extrinsic stimuli can initiate differentiation towards a specific cell type by triggering a tissue-specific
transcription factor, such as SOX5/6/9 for chondrocytes,
PPAR𝛾 for adipocytes, MyoD family for myoblasts, and
RUNX2/Osterix for osteoblasts [100]. Moreover, MSCs are
shown to transdifferentiate to lineages outside of the mesodermal lineage. In these complex differentiation processes,
IGFs are shown to play a role in fine-tuning transcription factor expression levels and activity and defining commitment
towards specific lineages from the three germ layers.
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7. The Role of IGFs in Mesenchymal Stem Cell
Fate Specification and Differentiation
7.1. Mesodermal Differentiation
7.1.1. Osteogenesis. IGF-1 and IGF-2 are secreted by skeletal bone cells for stimulation of bone formation, growth,
and metabolism and prevent apoptosis in a paracrine/autocrine manner [101, 102]. Local overexpression of IGF-1 in
osteoblasts can accelerate the rate of bone formation and
increase the pace of matrix mineralization, which is dependent on IGF-1R [103]. Decoupling of IGF-1R signaling from
IGF-1 is responsible for reduced proliferation/differentiation
in primary osteoblast from osteoporosis patients, hence
causing bone loss [104]. Under nondifferentiation conditions,
IGF-1 transfected human MSCs were able to upregulate
expression of various osteoblast genes [105]. For regeneration,
bone marrow MSCs (BM-MSCs) secrete IGF-1 and the use
of their conditioned media was required to restore alveolar
bone regeneration prior to dental implant placement [106]. In
dental pulp MSC differentiation, IGF-1 was shown to promote
mTOR signaling pathway in order to trigger the expression of
RUNX2, OCN, OSX, and COL1 [36]. Also, human deciduous
teeth MSCs with high osteopotential express and secrete IGF2 that is required for differentiation and mineralization [107].
Overall, IGF-1 and IGF-2 play a significant role in MSC
osteogenic differentiation and bone health.
7.1.2. Myogenesis. L6E9 cells (a myoblast cell line used in late
myogenesis studies), when stimulated with IGF-1, have an
initial proliferative response [108]. During rapid cell division,
the myogenic regulatory factors are inhibited, whereas, 30
hours later, the mitogenic effect is suppressed and Myogenin expression and activity are increased. Although the
downstream factors in IGF-mediated differentiation are still
under investigation, IGFs can induce myogenic transcription
factors. In contrast, the overexpression of MyoD (a protein
that plays a major role in regulating muscle differentiation)
in C3H 10T1/2 mouse embryonic fibroblast cells induces
IGF-2 expression which in turn activates IGF-1R and its
downstream target AKT [109]. Specifically, IGF-2 is required
for the recruitment and induction of myogenic promoters
and myogenesis [110]. In particular, IGF-2 is required to
allow continued recruitment of MyoD-associated proteins
at the Myogenin promoter [111]. Moreover, IGF-2 specific
binding protein, IGFBP-6, is expressed during embryonic
development in many different tissues including the ossifying
bones of the cranium, myoblasts, and the motor neurons of
the spinal cord [112].
The potential use of MSCs has been investigated in
treating muscular injury and myocardial infarction. Rat BMMSCs have been used as the source of paracrine factors
to treat soleus muscle injury [113]. Pretreatment of MSCs
with IGF-1 improves MSC healing ability by reducing scar
formation, increasing angiogenesis and faster reconstitution of muscle structure, and improving function [113]. In
another study, injection of BM-MSCs into the cardiac muscle
increased the proliferation and migration and inhibited apoptosis of existing cardiac muscle cells; however, IGF-1 does
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not induce myocardial differentiation of these MSCs [114]. In
addition, transplantation of IGF-1-primed MSCs attenuates
cardiac dysfunction, increases the survival of engrafted cells
in the ischemic heart, decreases myocardium cell apoptosis,
and inhibits the expression of inflammation cytokines such
as tumor necrosis factor-alpha (TNF-𝛼), interleukin-1𝛽 (IL1𝛽), and IL-6 [115]. The current research into MSCs and IGF
in myogenesis is, therefore, more focused on in vivo muscle
repair than on MSC-differentiated myoblast in transplantation.
7.1.3. Adipogenesis. In a comparative study between MSCs
from different sources including adipose stem cells (ASCs),
bone marrow stem cells (BMSCs), dermal sheath cells
(DSCs), and dermal papilla cells (DPCs), IGF-1 had the
highest expression and secretion in ASCs compared to
the other populations [116]. Also, IGF1 could promote lineage bias and selection for adipogenic progenitor (CD31−/
CD34+/CD146−) cells at the expense of the less adipogenic cells (CD31−/CD34+/CD146+) [37]. In this process, IGF-1 attenuates Wnt/𝛽-catenin signaling by activating Axin2/PPAR𝛾 pathways to promote the selection for
(CD31−/CD34+/CD146−) cells [37]. In another study, IGF1 was shown to alter MSC fate between osteogenic and
adipogenic lineages by its ability to bind and form a complex
with the acid-labile subunit (ALS) [117]. The loss of this IGF1/ALS complex shifted differentiation from osteogenesis to
adipogenesis [117].
7.1.4. Chondrogenesis. In an intervertebral disc degeneration
study, it was shown that IGF-1 and TGF-𝛽3 work in synergy to
enhance nucleus pulposus-derived mesenchymal stem cells
viability, extracellular matrix biosynthesis, and differentiation
towards nucleus pulposus cells [118]. Although TGF-𝛽 signaling is known to be important for chondroinductive differentiation from MSCs, more studies are showing that IGF1 can regulate MSC chondrogenesis independent of TGF-𝛽.
In one study, IGF-1 can induce chondrogenic differentiation
from adipose-derived MSCs with increased collagen type II,
Aggrecan, and SOX9 levels [38]. Similarly, IGF-1 induced
the chondrogenic potential of BM-derived MSCs stimulating
proliferation, regulating apoptosis, and inducing expression
of chondrogenic markers [119]. In this play of IGF-1 in
chondrogenesis, IRS-1 localization was induced from being
nuclear to being cytoplasmic to shift MSC proliferation to
differentiation [120].
7.2. Ectodermal Differentiation
7.2.1. Corneal and Neurogenesis. IGF-1 plays an important
role in ectodermal lineage differentiation. MSC differentiation towards neural progenitor cells (NPCs) is enhanced
by IGF-1 with increased expression of Nestin and the rate
of cell proliferation, while it inhibits apoptosis and induces
higher terminal differentiation of NPC towards neurons
and glial cells [40]. In another study, the administration
of IGF-1 alone in addition to corneal extract stimulated
differentiation of BM-MSCs into corneal-like cells more
efficiently [39]. Mice with reduced IGF-1R expression in
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the brain in conditional mutant 𝑛𝑒𝑠-𝐼𝑔𝑓1𝑟−/Wt demonstrate
greater neuronal damage following hypoxic-ischemic injury,
suggesting the importance of IGF-1R in neuronal cells,
including neuronal progenitor and stem cells [121]. IGFBP-2
promotes the keratocyte phenotype of differentiating human
corneal fibroblasts from MSCs by increasing the expression
of keratocan and ALDH1A1 and decreasing 𝛼-smooth muscle
actin [122]. In addition, IGF-1 overexpressing UC-MSCs are
able to differentiate more successfully to neural progenitor
cells producing more Pax6-positive cells and Nestin-positive
cells and could differentiate into astrocytes with higher
efficiency [123].
7.2.2. Epidermal and Dermal Lineages. The role of MSCs and
IGFs has been explored in the treatment of skin ulcers, particularly challenging clinical conditions like diabetes [124].
In the developing skin, IGF-1 is expressed in the stratum
granulosum, dermal fibroblasts, and the differentiating hair
follicles and sebaceous glands [125]. In particular, IGF-1 is
strongly expressed in the injury area, where it plays an
important role in both epidermal and dermal wound-healing
[126]. Recently, BM-MSCs were used in a rodent model of
diabetic foot ulceration and were demonstrated to improve
wound-healing and to increase the expression of local GFs
including IGF-1, EGF, and MMP2 [127].
7.3. Endodermal Differentiation
7.3.1. Endocrine Pancreas and Liver. MSC differentiation
towards 𝛽-cells, derived by stepwise media formulation, has
not been successful to generate fully functional and glucoseresponsive insulin-secreting 𝛽-cells. However, similar to
treating patients with cardiac infarction, MSC transplantation into diabetic patients is being investigated. Umbilical
cord MSCs injected in vivo in an induced diabetic rat model
were able to prevent hyperglycemic progression and preserve
islet size and cellularity; IGF-1 secreted by MSCs was responsible for islet viability and insulin secretion in vitro [128].
Therefore, IGF-1 is a prominent trophic factor in pancreatic
islet function and development, which may be required for 𝛽cell differentiation in vitro. In hepatocyte differentiation, IGF1 is expressed and required in the liver during development. It
was shown that the addition of IGF-1 to differentiation media
induced earlier hepatocyte morphology changes, albumin
and AFP expression, glycogen storage, urea production, and
albumin secretion [41].

8. Crosstalk between the IGF Axis
and Other Signaling Pathways in MSC
Proliferation and Differentiation
Adult MSCs express different genes associated with both
self-renewal and differentiation, including members of the
Notch, TGFB, FGF, WNT, IGF, hedgehog families, and
G-protein coupled receptor-mediated and cAMP-mediated
signaling [129]. Crosstalk between signaling pathways has
been shown to be important for stem cells’ self-renewal and
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differentiation; however, specific interactions with the IGF
system are still being delineated in MSCs.
As shown in Figure 1, integrins can play an important
role in IGF signaling. In particular, IGF-1 directly binds
to 𝛼v𝛽3 integrin and induces 𝛼v𝛽3-IGF1-IGF1R ternary
complex formation required for phosphorylation, ERK and
AKT activation, and cell proliferation [130].
In primary oligodendrocyte precursors, IGF-1 signaling
was shown to increase 𝛽-catenin protein abundance via the
IGF-1-induced phosphorylation of AKT and GSK3 required
for an increase in cyclin D1 mRNA, proliferation, and survival
[131].
To enhance migration and homing after transplantation,
IGF-1 upregulates the level of the CXCR4, receptor for the
chemokine stromal cell-derived factor-1, and SDF-1, in MSCs
and in turn can accelerate migration [132, 133]. In these
MSCs, CXCR4 upregulation is mediated by the PI3K/AKT
pathway downstream of the activated IGF-1R [133]. In vivo,
MSC preconditioning with IGF-1, before administration, was
shown to be effective in migration and homing which was
required for the restoration of renal function following acute
kidney injury [47].
In bone formation and osteoblast differentiation, IGF-2
was shown to potentiate the bone morphogenetic protein9 (BMP-9), which belongs to the transforming growth
factor-𝛽 (TGF-𝛽) superfamily [134]. IGF-2, mediated via
the PI3K/AKT, can potentiate BMP-9-induced activity of
the early osteogenic marker alkaline phosphatase (ALP) and
the expression of later markers such as osteocalcin and
osteopontin in MSCs. On the other hand, IGFBP3 and
IGFBP4 can inhibit the potentiation effect of IGF-2 on BMP9-induced ALP activity and matrix mineralization in MSCs
[134].
Also, in osteoblast differentiation of BM-MSCs, hedgehog
(HH) via Gli2 was shown to increase IGF-2 expression
that was acting via the IGF-1R/mTORC2/AKT [135]. IGF2-mediated AKT activation served as a positive feedback
loop for enhanced HH transcriptional output by stabilizing
full-length Gli2 due to phosphorylation by AKT. In myogenic differentiation, sonic hedgehog (SHH), member of
HH family, was also regarded as positive regulator of IGF-1
signaling in a cooperative additive effect in primary myoblast
proliferation and differentiation via the MAPK/ERK and
PI3K/AKT pathways [136]. In this process, Smoothened, a
SHH effector, can associate with IGF-1R and is required for
IGF-1 action via AKT, especially for differentiation.
Crosstalk between the IGF system and other pathways has
also been explored in cancer stem cells which may not be
dependent on their immediate niche but can give an insight
into normal MSCs [137]. In glioma stem cells (GSC), HH
via Gli1 upregulated the transcriptional activation of IRS-1
which increased GSC sensitivity to IGF-1 stimulation [138].
In lung adenocarcinoma stem-like cells, IGF-1R-mediated
OCT4 expression to form a complex with 𝛽-catenin and
SOX2 was crucial for the self-renewal and oncogenic potential [139]. Other signaling pathways are shown to interact with
the IGF system in many cell types that are still to be elucidated
in the MSC population and understand their effect in selfrenewal and differentiation.
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Table 1: MSC differentiation protocols with IGFs towards different lineages. Example of MSC differentiation protocols included IGFs in their
differentiation media formulations.
MSC population

Differentiation

Human dental pulp
stem cells

Osteoblast-like cells

Stromal vascular
fraction of adipose
tissue, human adipose
stem/progenitor cells

Adipocyte-like cells

Human
adipose-derived
mesenchymal cells

Chondrocyte-like
cells

Mouse bone marrow
mesenchymal stem
cells

Corneal-like cells

Rat bone marrow
mesenchymal stem
cells

Neural-like cells

Human bone marrow
mesenchymal stem
cells

Hepatocyte-like cell

9. IGF-Expressing MSCs in
Treating Terminal Diseases
Paracrine factors, including IGFs, secreted by MSCs are
shown to play a major role in treating organ-failure-causing
diseases. IGF-expressing MSCs were shown to enhance proliferation, differentiation, and repair of surrounding tissue
in kidney, heart, and pancreas [81–83]. In kidney ischemicreperfusion injury, physical interaction between MSC and
kidney tissue was required to promote kidney repair and
not only MSC conditioned media alone [83]. Genetically
engineered IGF-1-MSCs were used to treat liver cirrhosis
in mice [140]. Transplanted MSC induced higher IGF-1
and HGF expression with lowered TGF-𝛽1 levels and less
activation of hepatic satellite cells. IGF-1 effect was evident by
lowered collagen expression and fibrosis with more parenchymal cell proliferation as indication of liver regeneration.
Following myocardial infarction, it was shown that adult
human epicardium-derived cells and cardiomyocyte progenitor cells synergistically improve cardiac function, probably
instigated by complementary paracrine actions [141]. In fact,
cotransplantation of unmodified MSC plus cardiovascular
progenitors had elevated expression of factors promoting
cardiac repair specifically IGF1 that promoted expression of
prosurvival and angiogenesis genes in human cells [142].

Protocol
Osteogenic media supplemented with
0.1 𝜇mol/L dexamethasone, 10 mmol/L
b-glycerophosphate, 50 𝜇g/mL ascorbic acid,
and 100 ng/mL of IGF-1.

Reference

StemPro Adipogenesis Differentiation Kit
supplemented with 10 ng/mL of IGF-1.

[37]

DMEM high glucose supplemented with 1%
FBS, 0.1 mM ascorbic acid-2-phosphate, 10−7
dexamethasone, 6.25 𝜇g/mL transferrin,
6.25 ng/mL selenous acid, 10 ng/mL
recombinant human TGF-𝛽1, and 100 ng/mL
recombinant human IGF-1.
MSCs were cultured for 3, 7, or 10 days in
complete DMEM with 20% extract from the
corneas and 20 ng/mL IGF-1.
Proliferation media: NeuroCult NS-A
proliferation media specific for rat
supplemented with 20 ng/mL EGF, 20 ng/mL
bFGF, and 100 ng/mL IGF-1. Differentiation
media: NeuroCult supplemented with 10 ng/mL
PDGF-BB for glial induction or 10 ng/mL
rh-BDNF for neuronal differentiation.
Step 1: DMEM low glucose supplemented with
10% FBS, 20 ng/mL of IGF-I, 20 ng/mL of HGF,
and 10−7 M dexamethasone for 7 days. Step 2:
step 1 media with 10 ng/mL Oncostatin M for
14 days.

[36]

[38]

[39]

[40]

[41]

In induced diabetes STZ mice, MSC helped to attenuate
abnormal function of adipocytes, which are involved in
cutaneous wound-healing, by IGF-1 secretion [143]. IGF-1
in these mice helped in activating PI3K/AKT and GLUT4
which improved glucose uptake and insulin sensitivity, therefore improving diabetic wound-healing. In hepatocellular
carcinoma (HCC) treatment, fetal human MSCs conditioned
media were used to inhibit cell growth [144]. It was discovered
that the conditioned media contained high levels of IGFBPs
which sequestered IGFs and reduced IGF-1R and AKT
activation, leading to cell cycle arrest in HCC. These tumorspecific effects were not observed in matched hepatocytes or
patient-derived matched normal tissue. In all these examples,
MSCs expressing IGF system components are being used in
enhancing tissue repair of failing organs, fighting cancer, and
ameliorating diabetes.

10. Critical Use of IGF and Insulin in Cell
Culture Conditions
Addition of IGFs to differentiation media leads to earlier
commitment and higher onset of differentiation in several
lineages including endothelial, corneal, neural, chondrocyte,
adipocyte, hepatocytes, and osteoblast cells (Table 1). In
this context, a typical concentration of 10–100 ng/mL of
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IGF-1 is sufficient to activate only the IGF-1R and not the
IR. On the other hand, not much attention is given to
receptor binding affinity of IGF-1R versus IR, when insulin
is used in maintenance or differentiation conditions. The
inclusion in commercial biological products for stem cell
research of nonphysiological concentrations of insulin (0.5, 5,
and 10 𝜇g/mL) for MSC differentiation media is 100–1,000x
higher than highest insulin concentration in serum [145].
High concentrations of insulin (≥1 𝜇g/mL) not only activate
IR but also activate IGF-1R [44, 145]. Therefore, using such
high insulin concentrations in defined media, which can be
a substitute to IGFs, cannot distinguish whether the effect
is mediated via IGF-1R or IR signaling pathways and studies
describing the effect of IGFs in growth and/or differentiation
of stem cells in “defined medium” should recognize this
potential confounding effect.

11. Summary and Conclusions
IGFs are among the earliest growth factors to be expressed
in a developing embryo as early as in preimplantation
embryos and putatively act as autocrine/paracrine factors on
many developing cells including stem cells. They form an
important component of the stem cell niche. Their expression
is ubiquitous in many cell types; however, they are most
abundant in the cells and tissues of mesodermal origin. Thus,
MSCs are both the source and target of IGFs during development and likely play important roles in the maintenance
of pluripotency as well as determining their fate to lineages
of all three germ layers. Recent evidence also suggests the
potential discriminating roles of IGF-1 and IGF-2 in MSCs
and progenitor cells of different tissues. As MSCs are being
investigated as being important for cellular replacement and
regenerative therapies, delineating the roles of endogenous as
well as exogenous IGFs in MSC growth and differentiation
will be critical in developing these cellular therapies towards
treatment of many degenerative diseases that have no viable
therapeutic options at present.
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[37] L. Hu, G. Yang, D. Hägg et al., “IGF1 promotes adipogenesis by a
lineage bias of endogenous adipose stem/progenitor cells,” Stem
Cells, vol. 33, no. 8, pp. 2483–2495, 2015.
[38] Q. Zhou, B. Li, J. Zhao, W. Pan, J. Xu, and S. Chen, “IGF-I
induces adipose derived mesenchymal cell chondrogenic differentiation in vitro and enhances chondrogenesis in vivo,” In
Vitro Cellular and Developmental Biology—Animal, vol. 52, no.
3, pp. 356–364, 2016.
[39] P. Trosan, E. Javorkova, A. Zajicova et al., “The supportive role
of insulin-like growth factor-I in the differentiation of murine
mesenchymal stem cells into corneal-like cells,” Stem Cells and
Development, vol. 25, no. 11, pp. 874–881, 2016.
[40] T. J. Huat, A. A. Khan, S. Pati, Z. Mustafa, J. M. Abdullah,
and H. Jaafar, “IGF-1 enhances cell proliferation and survival

9

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]
[49]

[50]

[51]

[52]
[53]

[54]

[55]

[56]

during early differentiation of mesenchymal stem cells to neural
progenitor-like cells,” BMC Neuroscience, vol. 15, article no. 91,
2014.
M. Ayatollahi, M. Soleimani, B. Geramizadeh, and M. H.
Imanieh, “Insulin-like growth factor 1 (IGF-I) improves hepatic
differentiation of human bone marrow-derived mesenchymal
stem cells,” Cell Biology International, vol. 35, no. 11, pp. 1169–
1176, 2011.
A. A. Butler, S. Yakar, I. H. Gewolb, M. Karas, Y. Okubo, and
D. LeRoith, “Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology,”
Comparative Biochemistry and Physiology Part B: Biochemistry
& Molecular Biology, vol. 121, no. 1, pp. 19–26, 1998.
E. Rinderknecht and R. E. Humbel, “The amino acid sequence
of human insulin-like growth factor I and its structural homology with proinsulin,” Journal of Biological Chemistry, vol. 253,
no. 8, pp. 2769–2776, 1978.
R. Rubin and R. Baserga, “Insulin-like growth factor-I receptor:
its role in cell proliferation, apoptosis, and tumorigenicity,”
Laboratory Investigation, vol. 73, no. 3, pp. 311–331, 1995.
T. S. Olson, M. J. Bamberger, and M. D. Lane, “Post-translational
changes in tertiary and quaternary structure of the insulin
proreceptor. Correlation with acquisition of function,” Journal
of Biological Chemistry, vol. 263, no. 15, pp. 7342–7351, 1988.
F. Frasca, G. Pandini, P. Scalia et al., “Insulin receptor isoform A,
a newly recognized, high-affinity insulin- like growth factor
II receptor in fetal and cancer cells,” Molecular and Cellular
Biology, vol. 19, no. 5, pp. 3278–3288, 1999.
C. Xinaris, M. Morigi, V. Benedetti et al., “A novel strategy to
enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury specific fashion,” Cell Transplantation, vol. 22, no. 3, pp. 423–436, 2013.
D. R. Clemmons, “IGF binding proteins: regulation of cellular
actions,” Growth Regulation, vol. 2, no. 2, pp. 80–87, 1992.
J. I. Jones and D. R. Clemmons, “Insulin-like growth factors and
their binding proteins: biological actions,” Endocrine Reviews,
vol. 16, no. 1, pp. 3–34, 1995.
K. M. Kelley, Y. Oh, S. E. Gargosky et al., “Insulin-like growth
factor-binding proteins (IGFBPs) and their regulatory dynamics,” International Journal of Biochemistry and Cell Biology, vol.
28, no. 6, pp. 619–637, 1996.
S. Shimasaki and N. Ling, “Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP1, -2, -3, -4, -5 and -6),” Progress in Growth Factor Research, vol.
3, no. 4, pp. 243–266, 1991.
W. S. Cohick and D. R. Clemmons, “The insulin-like growth
factors,” Annual Review of Physiology, vol. 55, pp. 131–153, 1993.
A. Grimberg and P. Cohen, “Role of insulin-like growth factors
and their binding proteins in growth control and carcinogenesis,” Journal of Cellular Physiology, vol. 183, no. 1, pp. 1–9, 2000.
L. A. Bach, S. J. Headey, and R. S. Norton, “IGF-binding
proteins—the pieces are falling into place,” Trends in Endocrinology and Metabolism, vol. 16, no. 5, pp. 228–234, 2005.
R. Baserga, A. Hongo, M. Rubini, M. Prisco, and B. Valentinis,
“The IGF-I receptor in cell growth, transformation and apoptosis,” Biochimica et Biophysica Acta, vol. 1332, no. 3, pp. F105–
F126, 1997.
L. A. Bach, S. Hsieh, K.-I. Sakano, H. Fujiwara, J. F. Perdue,
and M. M. Rechler, “Binding of mutants of human insulin-like
growth factor II to insulin-like growth factor binding proteins
1–6,” Journal of Biological Chemistry, vol. 268, no. 13, pp. 9246–
9254, 1993.

10
[57] S. Benyoucef, K. H. Surinya, D. Hadaschik, and K. Siddle, “Characterization of insulin/IGF hybrid receptors: contributions
of the insulin receptor L2 and Fn1 domains and the alternatively
spliced exon 11 sequence to ligand binding and receptor activation,” Biochemical Journal, vol. 403, no. 3, pp. 603–613, 2007.
[58] R. Baserga, “The insulin receptor substrate-1: a biomarker for
cancer?” Experimental Cell Research, vol. 315, no. 5, pp. 727–732,
2009.
[59] J.-C. Chambard, R. Lefloch, J. Pouysségur, and P. Lenormand,
“ERK implication in cell cycle regulation,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1773, no. 8, pp. 1299–
1310, 2007.
[60] P. W. Zandstra and A. Nagy, “Stem cell bioengineering,” Annual
Review of Biomedical Engineering, vol. 3, pp. 275–305, 2001.
[61] K. Forbes and M. Westwood, “The IGF axis and placental
function: a mini review,” Hormone Research, vol. 69, no. 3, pp.
129–137, 2008.
[62] M. G. Myers Jr., T. C. Grammer, L.-M. Wang et al., “Insulin
receptor substrate-1 mediates phosphatidylinositol 3-kinase
and p70S6k signaling during insulin, insulin-like growth factor1, and interleukin-4 stimulation,” Journal of Biological Chemistry, vol. 269, no. 46, pp. 28783–28789, 1994.
[63] P. van der Geer, S. Wiley, G. D. Gish et al., “Identification
of residues that control specific binding of the Shc phosphotyrosine-binding domain to phosphotyrosine sites,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 93, no. 3, pp. 963–968, 1996.
[64] P. Van Der Geer, S. Wiley, G. D. Gish, and T. Pawson, “The Shc
adaptor protein is highly phosphorylated at conserved, twin
tyrosine residues (Y239/240) that mediate protein-protein
interactions,” Current Biology, vol. 6, no. 11, pp. 1435–1444, 1996.
[65] J. Blenis, “Signal transduction via the MAP kinases: proceed at
your own RSK,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 90, no. 13, pp. 5889–5892,
1993.
[66] B. Margolis and E. Y. Skolnik, “Activation of ras by receptor
tyrosine kinases,” Journal of the American Society of Nephrology,
vol. 5, no. 6, pp. 1288–1299, 1994.
[67] B. Lamothe, D. Bucchini, J. Jami, and R. L. Joshi, “Interaction
of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors
analysed by using the two-hybrid system,” FEBS Letters, vol. 373,
no. 1, pp. 51–55, 1995.
[68] B. Valentinis and R. Baserga, “IGF-I receptor signalling in
transformation and differentiation,” Molecular Pathology, vol.
54, no. 3, pp. 133–137, 2001.
[69] D. L. Esposito, Y. Li, A. Cama, and M. J. Quon, “Tyr612 and
Tyr632 in human insulin receptor substrate-1 are important
for full activation of insulin-stimulated phosphatidylinositol 3kinase activity and translocation of GLUT4 in adipose cells,”
Endocrinology, vol. 142, no. 7, pp. 2833–2840, 2001.
[70] C. T. Roberts, J. A. Owens, A. M. Carter, J. E. Harding, R.
Austgulen, and M. Wlodek, “Insulin-like growth factors and
foetal programming—a workshop report,” Placenta, vol. 24, pp.
S72–S75, 2003.
[71] J.-P. Liu, J. Baker, A. S. Perkins, E. J. Robertson, and A. Efstratiadis, “Mice carrying null mutations of the genes encoding
insulin-like growth factor I (Igf-1) and type 1 IGF receptor
(Igf1r),” Cell, vol. 75, no. 1, pp. 59–72, 1993.
[72] J. Wang, J. Zhou, and C. A. Bondy, “Igf1 promotes longitudinal
bone growth by insulin-like actions augmenting chondrocyte
hypertrophy,” FASEB Journal, vol. 13, no. 14, pp. 1985–1990, 1999.

Stem Cells International
[73] L. Rodriguez-de la Rosa, L. Fernandez-Sanchez, F. Germain et
al., “Age-related functional and structural retinal modifications
in the Igf1-/- null mouse,” Neurobiology of Disease, vol. 46, no.
2, pp. 476–485, 2012.
[74] T. M. DeChiara, A. Efstratiadis, and E. J. Robertsen, “A growthdeficiency phenotype in heterozygous mice carrying an insulinlike growth factor II gene disrupted by targeting,” Nature, vol.
345, no. 6270, pp. 78–80, 1990.
[75] A. A. Butler and D. LeRoith, “Tissue-specific versus generalized
gene targeting of the IGF1 and IGF1R genes and their roles in
insulin-like growth factor physiology,” Endocrinology, vol. 142,
no. 5, pp. 1685–1688, 2001.
[76] J.-L. Liu, S. Yakar, and D. Leroith, “Conditional knockout of
mouse insulin-like growth factor-1 gene using the Cre/loxP
system,” Proceedings of the Society for Experimental Biology and
Medicine, vol. 223, no. 4, pp. 344–351, 2000.
[77] M. H.-C. Sheng, X.-D. Zhou, L. F. Bonewald, D. J. Baylink, and
K.-H. W. Lau, “Disruption of the insulin-like growth factor-1
gene in osteocytes impairs developmental bone growth in mice,”
Bone, vol. 52, no. 1, pp. 133–144, 2013.
[78] C. D. De Magalhaes Filho, L. Kappeler, J. Dupont et al., “Deleting IGF-1 receptor from forebrain neurons confers neuroprotection during stroke and upregulates endocrine somatotropin,”
Journal of Cerebral Blood Flow & Metabolism, vol. 37, no. 2, pp.
396–412, 2017.
[79] Z. Chaker, S. Aı̈d, H. Berry, and M. Holzenberger, “Suppression
of IGF-I signals in neural stem cells enhances neurogenesis and
olfactory function during aging,” Aging Cell, vol. 14, no. 5, pp.
847–856, 2015.
[80] A. Youssef and V. K. M. Han, “Low oxygen tension modulates
the insulin-like growth factor-1 or -2 signaling via both insulinlike growth factor-1 receptor and insulin receptor to maintain stem cell identity in placental mesenchymal stem cells,”
Endocrinology, vol. 157, no. 3, pp. 1163–1174, 2016.
[81] K. Yamahara, K. Harada, M. Ohshima et al., “Comparison of
angiogenic, cytoprotective, and immunosuppressive properties
of human amnion- and chorion-derived mesenchymal stem
cells,” PLoS ONE, vol. 9, no. 2, Article ID e88319, 2014.
[82] S. Sadat, S. Gehmert, Y.-H. Song et al., “The cardioprotective
effect of mesenchymal stem cells is mediated by IGF-I and
VEGF,” Biochemical and Biophysical Research Communications,
vol. 363, no. 3, pp. 674–679, 2007.
[83] L. Xing, R. Cui, L. Peng et al., “Mesenchymal stem cells, not
conditioned medium, contribute to kidney repair after ischemia-reperfusion injury,” Stem Cell Research and Therapy, vol. 5,
no. 4, article no. 101, 2014.
[84] C. Hu, Y. Wu, Y. Wan, Q. Wang, and J. Song, “Introduction of
hIGF-1 gene into bone marrow stromal cells and its effects on
the cell’s biological behaviors,” Cell Transplantation, vol. 17, no.
9, pp. 1067–1081, 2008.
[85] M. H. Stewart, S. C. Bendall, and M. Bhatia, “Deconstructing
human embryonic stem cell cultures: niche regulation of selfrenewal and pluripotency,” Journal of Molecular Medicine, vol.
86, no. 8, pp. 875–886, 2008.
[86] S.-B. Park, K.-R. Yu, J.-W. Jung et al., “BFGF enhances the
IGFs-mediated pluripotent and differentiation potentials in
multipotent stem cells,” Growth Factors, vol. 27, no. 6, pp. 425–
437, 2009.
[87] A. Youssef, C. Iosef, and V. K. M. Han, “Low-oxygen tension
and IGF-I promote proliferation and multipotency of placental
mesenchymal stem cells (PMSCs) from different gestations via

Stem Cells International

[88]

[89]

[90]

[91]

[92]

[93]

[94]

[95]

[96]

[97]

[98]

[99]

[100]

[101]
[102]

[103]

[104]

distinct signaling pathways,” Endocrinology, vol. 155, no. 4, pp.
1386–1397, 2014.
R. Montes, G. Ligero, L. Sanchez et al., “Feeder-free maintenance of hESCs in mesenchymal stem cell-conditioned media:
distinct requirements for TGF-beta and IGF-II,” Cell Research,
vol. 19, no. 6, pp. 698–709, 2009.
H. Lee, H. Chang, S. Lee et al., “Role of IGF1R+ MSCs in modulating neuroplasticity via CXCR4 cross-interaction,” Scientific Reports, vol. 6, Article ID 32595, 2016.
A. N. Ziegler, J. S. Schneider, M. Qin et al., “IGF-II promotes
stemness of neural restricted precursors,” Stem Cells, vol. 30, no.
6, pp. 1265–1276, 2012.
A. N. Ziegler, S. Chidambaram, B. E. Forbes, T. L. Wood, and
S. W. Levison, “Insulin-like growth factor-II (IGF-II) and IGFII Analogs with enhanced insulin receptor-a binding affinity
promote neural stem cell expansion,” Journal of Biological
Chemistry, vol. 289, no. 8, pp. 4626–4633, 2014.
A. N. Ziegler, S. W. Levison, and T. L. Wood, “Insulin and IGF
receptor signalling in neural-stem-cell homeostasis,” Nature
Reviews Endocrinology, vol. 11, no. 3, pp. 161–170, 2015.
I. Sancho-Martinez, S. H. Baek, and J. C. Izpisua Belmonte,
“Lineage conversion methodologies meet the reprogramming
toolbox,” Nature Cell Biology, vol. 14, no. 9, pp. 892–899, 2012.
J. Y. Lee, Z. Zhou, P. J. Taub et al., “BMP-12 treatment of adult
mesenchymal stem cells in vitro augments tendon-like tissue
formation and defect repair in vivo,” PLoS ONE, vol. 6, no. 3,
Article ID e17531, 2011.
P. De Coppi, G. Bartsch Jr., M. M. Siddiqui et al., “Isolation
of amniotic stem cell lines with potential for therapy,” Nature
Biotechnology, vol. 25, no. 1, pp. 100–106, 2007.
N. Wang, R. Zhang, S.-J. Wang et al., “Vascular endothelial
growth factor stimulates endothelial differentiation from mesenchymal stem cells via Rho/myocardin-related transcription
factor—a signaling pathway,” International Journal of Biochemistry and Cell Biology, vol. 45, no. 7, pp. 1447–1456, 2013.
J. Oswald, S. Boxberger, B. Jørgensen et al., “Mesenchymal stem
cells can be differentiated into endothelial cells in vitro,” Stem
Cells, vol. 22, no. 3, pp. 377–384, 2004.
A. S. de la Garza-Rodea, I. van der Velde-van Dijke, H. Boersma
et al., “Myogenic properties of human mesenchymal stem cells
derived from three different sources,” Cell Transplantation, vol.
21, no. 1, pp. 153–173, 2012.
Y.-H. Zheng, W. Xiong, K. Su, S.-J. Kuang, and Z.-G. Zhang,
“Multilineage differentiation of human bone marrow mesenchymal stem cells in vitro and in vivo,” Experimental and Therapeutic Medicine, vol. 5, no. 6, pp. 1576–1580, 2013.
T. Katagiri and N. Takahashi, “Regulatory mechanisms of
osteoblast and osteoclast differentiation,” Oral Diseases, vol. 8,
no. 3, pp. 147–159, 2002.
S. Mohan and D. J. Baylink, “Bone growth factors,” Clinical
Orthopaedics and Related Research, no. 263, pp. 30–48, 1991.
T. Niu and C. J. Rosen, “The insulin-like growth factor-I gene
and osteoporosis: a critical appraisal,” Gene, vol. 361, no. 1-2, pp.
38–56, 2005.
T. L. Clemens and S. D. Chernausek, “Genetic strategies for
elucidating insulin-like growth factor action in bone,” Growth
Hormone & IGF Research, vol. 14, no. 3, pp. 195–199, 2004.
S. Perrini, A. Natalicchio, L. Laviola et al., “Abnormalities
of insulin-like growth factor-I signaling and impaired cell
proliferation in osteoblasts from subjects with osteoporosis,”
Endocrinology, vol. 149, no. 3, pp. 1302–1313, 2008.

11
[105] H. Koch, J. A. Jadlowiec, and P. G. Campbell, “Insulin-like
growth factor-I induces early osteoblast gene expression in
human mesenchymal stem cells,” Stem Cells and Development,
vol. 14, no. 6, pp. 621–631, 2005.
[106] W. Katagiri, M. Osugi, T. Kawai, and H. Hibi, “First-in-human
study and clinical case reports of the alveolar bone regeneration
with the secretome from human mesenchymal stem cells,” Head
and Face Medicine, vol. 12, no. 1, article no. 5, 2016.
[107] R. D. Fanganiello, F. A. A. Ishiy, G. S. Kobayashi, L. Alvizi,
D. Y. Sunaga, and M. R. Passos-Bueno, “Increased in vitro
osteopotential in SHED associated with higher IGF2 expression
when compared with hASCs,” Stem Cell Reviews and Reports,
vol. 11, no. 4, article A010, pp. 635–644, 2015.
[108] A. G. Miller, J. D. Aplin, and M. Westwood, “Adenovirally
mediated expression of insulin-like growth factors enhances the
function of first trimester placental fibroblasts,” The Journal of
Clinical Endocrinology and Metabolism, vol. 90, no. 1, pp. 379–
385, 2005.
[109] T. E. Adams, V. C. Epa, T. P. J. Garrett, and C. W. Ward,
“Structure and function of the type 1 insulin-like growth factor
receptor,” Cellular and Molecular Life Sciences, vol. 57, no. 7, pp.
1050–1093, 2000.
[110] E. M. Wilson and P. Rotwein, “Control of MyoD function
during initiation of muscle differentiation by an autocrine
signaling pathway activated by insulin-like growth factor-II,”
Journal of Biological Chemistry, vol. 281, no. 40, pp. 29962–
29971, 2006.
[111] P. Putzer, P. Breuer, W. Götz et al., “Mouse insulin-like growth
factor binding protein-6: expression, purification, characterization and histochemical localization,” Molecular and Cellular
Endocrinology, vol. 137, no. 1, pp. 69–78, 1998.
[112] M. R. Schneider, H. Lahm, M. Wu, A. Hoeflich, and E. Wolf,
“Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins,” FASEB Journal, vol. 14,
no. 5, pp. 629–640, 2000.
[113] M. Pumberger, T. H. Qazi, M. C. Ehrentraut et al., “Synthetic
niche to modulate regenerative potential of MSCs and enhance
skeletal muscle regeneration,” Biomaterials, vol. 99, pp. 95–108,
2016.
[114] G.-W. Zhang, T.-X. Gu, X.-Y. Guan et al., “HGF and IGF-1 promote protective effects of allogeneic BMSC transplantation in
rabbit model of acute myocardial infarction,” Cell Proliferation,
vol. 48, no. 6, pp. 661–670, 2015.
[115] J. Guo, D. Zheng, W.-F. Li, H.-R. Li, A.-D. Zhang, and Z.-C.
Li, “Insulin-like growth factor 1 treatment of MSCs attenuates
inflammation and cardiac dysfunction following MI,” Inflammation, vol. 37, no. 6, pp. 2156–2163, 2014.
[116] S. T.-F. Hsiao, A. Asgari, Z. Lokmic et al., “Comparative analysis
of paracrine factor expression in human adult mesenchymal
stem cells derived from bone marrow, adipose, and dermal
tissue,” Stem Cells and Development, vol. 21, no. 12, pp. 2189–
2203, 2012.
[117] J. C. Fritton, Y. Kawashima, W. Mejia et al., “The insulin-like
growth factor-1 binding protein acid-labile subunit alters mesenchymal stromal cell fate,” Journal of Biological Chemistry, vol.
285, no. 7, pp. 4709–4714, 2010.
[118] Y. Tao, X. Zhou, C. Liang et al., “TGF- 𝛽 3 and IGF-1
synergy ameliorates nucleus pulposus mesenchymal stem cell
differentiation towards the nucleus pulposus cell type through
MAPK/ERK signaling,” Growth Factors, vol. 33, no. 5-6, pp.
326–336, 2015.

12
[119] L. Longobardi, L. O’Rear, S. Aakula et al., “Effect of IGF-I in the
chondrogenesis of bone marrow mesenchymal stem cells in the
presence or absence of TGF-𝛽 signaling,” Journal of Bone and
Mineral Research, vol. 21, no. 4, pp. 626–636, 2006.
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[126] V. Todorović, P. Peško, M. Micev et al., “Insulin-like growth
factor-I in wound healing of rat skin,” Regulatory Peptides, vol.
150, no. 1–3, pp. 7–13, 2008.
[127] J. Kato, H. Kamiya, T. Himeno et al., “Mesenchymal stem
cells ameliorate impaired wound healing through enhancing
keratinocyte functions in diabetic foot ulcerations on the
plantar skin of rats,” Journal of Diabetes and Its Complications,
vol. 28, no. 5, pp. 588–595, 2014.
[128] Y. Zhou, Q. Hu, F. Chen et al., “Human umbilical cord matrixDerived stem cells exert trophic effects on 𝛽-cell survival in
diabetic rats and isolated islets,” DMM Disease Models and
Mechanisms, vol. 8, no. 12, pp. 1625–1633, 2015.
[129] T. L. B. Spitzer, A. Rojas, Z. Zelenko et al., “Perivascular
human endometrial mesenchymal stem cells express pathways
relevant to self-renewal, lineage specification, and functional
phenotype,” Biology of Reproduction, vol. 86, no. 2, article 58,
2012.
[130] J. Saegusa, S. Yamaji, K. Ieguchi et al., “The direct binding of
insulin-like growth factor-1 (IGF-1) to integrin 𝛼v𝛽3 is involved
in IGF-1 signaling,” The Journal of Biological Chemistry, vol. 284,
no. 36, pp. 24106–24114, 2009.
[131] P. Ye, Q. Hu, H. Liu, Y. Yan, and A. J. D’Ercole, “𝛽-catenin
mediates insulin-like growth factor-I actions to promote cyclin
D1 mRNA expression, cell proliferation and survival in oligodendroglial cultures,” GLIA, vol. 58, no. 9, pp. 1031–1041, 2010.
[132] Y.-L. Huang, R.-F. Qiu, W.-Y. Mai et al., “Effects of insulin-like
growth factor-1 on the properties of mesenchymal stem cells in
vitro,” Journal of Zhejiang University: Science B, vol. 13, no. 1, pp.
20–28, 2012.
[133] Y. Li, X. Yu, S. Lin, X. Li, S. Zhang, and Y.-H. Song, “Insulinlike growth factor 1 enhances the migratory capacity of mesenchymal stem cells,” Biochemical and Biophysical Research
Communications, vol. 356, no. 3, pp. 780–784, 2007.

Stem Cells International
[134] L. Chen, W. Jiang, J. Huang et al., “Insulin-like growth factor 2
(IGF-2) potentiates BMP-9-induced osteogenic differentiation
and bone formation,” Journal of Bone and Mineral Research, vol.
25, no. 11, pp. 2447–2459, 2010.
[135] Y. Shi, J. Chen, C. M. Karner, and F. Long, “Hedgehog signaling
activates a positive feedback mechanism involving insulin-like
growth factors to induce osteoblast differentiation,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 112, no. 15, pp. 4678–4683, 2015.
[136] D. Madhala-Levy, V. C. Williams, S. M. Hughes, R. Reshef, and
O. Halevy, “Cooperation between Shh and IGF-I in promoting
myogenic proliferation and differentiation via the MAPK/ERK
and PI3K/Akt pathways requires smo activity,” Journal of
Cellular Physiology, vol. 227, no. 4, pp. 1455–1464, 2012.
[137] L. Li and W. B. Neaves, “Normal stem cells and cancer stem cells:
the niche matters,” Cancer Research, vol. 66, no. 9, pp. 4553–
4557, 2006.
[138] A. Hsieh, R. Ellsworth, and D. Hsieh, “Hedgehog/GLI1 regulates
IGF dependent malignant behaviors in glioma stem cells,”
Journal of Cellular Physiology, vol. 226, no. 4, pp. 1118–1127, 2011.
[139] C. Xu, D. Xie, S.-C. Yu et al., “𝛽-catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling
and predicts poor prognosis in lung adenocarcinoma,” Cancer
Research, vol. 73, no. 10, pp. 3181–3189, 2013.
[140] E. J. Fiore, J. M. Bayo, M. G. Garcia et al., “Mesenchymal stromal
cells engineered to produce IGF-I by recombinant adenovirus
ameliorate liver fibrosis in mice,” Stem Cells and Development,
vol. 24, no. 6, pp. 791–801, 2015.
[141] E. M. Winter, A. A. M. Van Oorschot, B. Hogers et al., “A new
direction for cardiac regeneration therapy: application of synergistically acting epicardium-derived cells and cardiomyocyte
progenitor cells,” Circulation: Heart Failure, vol. 2, no. 6, pp.
643–653, 2009.
[142] M. Kearns-Jonker, W. Dai, M. Gunthart et al., “Genetically engineered mesenchymal stem cells influence gene expression in
donor cardiomyocytes and the recipient heart,” Journal of Stem
Cell Research & Therapy, supplement 1, article 005, 2012.
[143] D. Gao, J. Xie, J. Zhang et al., “MSC attenuate diabetes-induced
functional impairment in adipocytes via secretion of insulinlike growth factor-1,” Biochemical and Biophysical Research
Communications, vol. 452, no. 1, pp. 99–105, 2014.
[144] Y. Yulyana, I. A. W. Ho, K. C. Sia et al., “Paracrine factors of
human fetal MSCs inhibit liver cancer growth through reduced
activation of IGF-1R/PI3K/Akt signaling,” Molecular Therapy,
vol. 23, no. 4, pp. 746–756, 2015.
[145] C. Kuhn, S. A. Hurwitz, M. G. Kumar, J. Cotton, and D. F.
Spandau, “Activation of the insulin-like growth factor-1 receptor
promotes the survival of human keratinocytes following ultraviolet B irradiation,” International Journal of Cancer, vol. 80, no.
3, pp. 431–438, 1999.

International Journal of

Peptides

BioMed
Research International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Advances in

Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com

International Journal of

Genomics

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Nucleic Acids

Zoology

International Journal of

Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Submit your manuscripts at
https://www.hindawi.com
The Scientific
World Journal

Journal of

Signal Transduction
Hindawi Publishing Corporation
http://www.hindawi.com

Genetics
Research International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Anatomy
Research International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Enzyme
Research

Archaea
Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Biochemistry
Research International

International Journal of

Microbiology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

International Journal of

Evolutionary Biology
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Molecular Biology
International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Advances in

Bioinformatics
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Marine Biology
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

